Treatment challenges in and outside a network setting: Head and neck cancers

Publication date: January 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 1Author(s): Ester Orlandi, Salvatore Alfieri, Christian Simon, Annalisa Trama, Lisa Licitra, Monika Hackl, Elizabeth Van Eycken, Kris Henau, Nadya Dimitrova, Mario Sekerija, Ladislav Dušek, Margit Mägi, Nea Malila, Maarit Leinonen, Michel Velten, Xavier Troussard, Veronique Bouvier, Anne-Valérie Guizard, Anne-Marie Bouvier, Patrick ArveuxAbstractHead and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe.Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect.Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lead to improved survival rates. This result is likely due to improved diagnostic and staging accuracy, a more efficacious therapeutic approach and enhanced communication across disciplines. Despite the benefit of MTD, it must be noted that this approach requires considerable time, effort and financial resources and is usually more frequent in...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion.We identified that the pathophysiology of sporadic MTC involve numerous pathways, including the synaptic vesicle pathway, the MAPK signaling pathway, and the ECM remodeling pathway. Furthermore, our study also identified FN1 as novel prognostic biomarkers related to the pathophysiologic changes in sporadic MTC.Implications for Practice.Proteomic dissection and prognostic biomarkers are scarce in sporadic medullary thyroid cancer (MTC). This article reports the use of proteomics technology to comprehensively investigate the molecular mechanisms of sporadic MTC, which resulted in the identification of FN1 as a nov...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Head and Neck Cancers, Cancer Diagnostics and Molecular Pathology, Endocrinology Source Type: research
Abstract Salivary gland cancer is an aggressive and painful cancer, but a rare tumor type accounting for only ~0.5% of cancer cases. Tumors of the salivary gland exhibit heterogeneous histologic and genetic features and they are subdivided into different subtypes, with adenoid cystic carcinomas (ACC) being one of the most abundant. Treatment of ACC patients is afflicted by high recurrence rates, the high potential of the tumors to metastasize, as well as the poor response of ACC to chemotherapy. A prerequisite for the development of targeted therapies is insightful genetic information for driver core cancer pathways. Here,...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Salivary gland cancer is a rare disease that accounts for approximately 5% of all head and neck cancers and 0.3% of all human cancers [1 –3]. Salivary gland carcinoma arises in various regions of the major and minor salivary glands, presenting at least 24 different histological subtypes with different clinical features of metastasis and recurrence [4,5]. Distant metastases are relatively common in salivary gland carcinoma [6], and may be present at initial presentation or may emerge during the post-treatment period.
Source: Oral Oncology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThis study identified male gender and high histological tumor grade as poor prognostic indicators; however, it did not reveal a statistically significant relationship between treatment modality and patient outcomes. Data regarding patient outcomes following treatment was limited due to loss to follow‐up, suggesting that further investigation is required. Based on this review, decisions regarding treatment should be clinically guided and individually tailored to the patient's baseline health, disease severity, and the patient's treatment goals. A multi‐disciplinary conference, as was utilized in the presented ...
Source: The Laryngoscope - Category: ENT & OMF Authors: Tags: Head and Neck Source Type: research
PRINCETON, NJ – July 27, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
ConclusionsDespite adequate primary treatment, distant and disseminated metastatic disease may be not excluded in leiomyosarcoma of the head and neck.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
PRINCETON, NJ – May 18, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
PRINCETON, NJ – May 3, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
ConclusionsIJV tumor thrombosis originated from SCC apparently reflects extremely aggressive state of the tumor. Recognition and precaution to this condition is essential for the development of a clinically effective treatment strategy.
Source: Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Rare Diseases | Surgery | Training | Universities & Medical Training